Compare SWBI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWBI | ANL |
|---|---|---|
| Founded | 1852 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.3M | 731.6M |
| IPO Year | 2000 | 2022 |
| Metric | SWBI | ANL |
|---|---|---|
| Price | $15.21 | $11.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $14.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 386.4K | 289.2K |
| Earning Date | 06-17-2026 | 04-10-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $474,661,000.00 | N/A |
| Revenue This Year | $7.61 | $36.02 |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | $309.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.73 | $0.88 |
| 52 Week High | $15.79 | $17.25 |
| Indicator | SWBI | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 46.83 |
| Support Level | $13.90 | $11.86 |
| Resistance Level | $15.24 | $15.63 |
| Average True Range (ATR) | 0.42 | 1.36 |
| MACD | 0.01 | -0.36 |
| Stochastic Oscillator | 68.48 | 33.40 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.